Navigation Links
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
Date:7/7/2009

n was a professor at Stanford University and the University of California, Berkeley and is currently an adjunct professor at UCSF in the Departments of Anatomy and Biochemistry. While on the faculty at Berkeley, he was an investigator with the Howard Hughes Medical Institute, Evan Rauch Professor of Neuroscience, co-founder of the Wills Neuroscience Institute, and head of the division of neurobiology. Dr. Goodman also is a member of the National Academy of Sciences and was chairman of the National Research Council's board on Life Sciences, which issued in 2002 the landmark national report "Stem Cells and the Future of Regenerative Medicine.
  • Dr. Lee Rubin is director of Translational Medicine at the Harvard Stem Cell Institute. His research has focused on identifying therapeutics for disorders such as SMA, ALS, Huntington's disease and multiple sclerosis using novel stem cell-based screens and assays.
  • Dr. Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a professor of Neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on Alzheimer's disease and related neurodegenerative disorders.
  • Dr. Benoit Bruneau is an associate investigator at the Gladstone Institute of Cardiovascular Disease and associate professor in the department of Pediatrics at UCSF, and is an expert in cardiac differentiation. Dr. Bruneau's research focuses on the transcriptional regulation of heart development.
  • Dr. Kevin Eggan, assistant professor in the Department of Stem Cell and Regenerative Biology at Harvard University, principal investigator at the Harvard Stem Cell Institute, and assistant investigator at the Stowers Medical Institute. Dr. Eggan is a world authority on somatic cell reprogramming by nuclear transfer, and the applications of iPS cells to model ne
    '/>"/>

  • SOURCE iZumi Bio, Inc.; Pierian, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
    2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
    3. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
    4. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
    5. iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
    6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
    8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    9. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
    10. IsoTis - Integra Merger
    11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
    (Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
    (Date:2/26/2015)... According to a new market report published by ... (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products and ... and Forecast, 2013 – 2019,”the global agricultural biotechnology market ... is expected to reach USD 28,694.1 million by 2019, ... 2019. , Demand for food production has increased ...
    (Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
    Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
    ... , , , ... AMGN ) today announced detailed results from a Phase ... the treatment of bone metastases in 2,046 patients with advanced ... demonstrated superior efficacy compared to Zometa. These results were presented ...
    ... ... answer the question, "Is the Jatropha sector becoming a DotCom Bubble?". 2nd JatrophaWorld ... Viridesco Ltd. will discuss the challenges, controversies & paradoxes of the nascent Jatropha non-food ... ...
    ... has become just another fixture, it,s time to take a ... used to develop paper-based biosensors that can detect certain harmful ... bioterrorism agents. In a paper published in the July ... research team at McMaster University, working with the Sentinel Bioactive ...
    Cached Biology Technology:Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 2Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 4Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 5Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 6Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 7Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 8Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 9Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel 2Toxin detection as close as an inkjet printer 2
    (Date:2/19/2015)... Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ... "Military Electro-Optical / Infrared Systems Market by Type, ... Forecast to 2020" report to their offering. ... is expected to reach $16.35 billion by 2020, ... This report segments the military electro-optical/infrared systems market ...
    (Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
    (Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
    Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
    ... April 2012 -- New techniques for identifying lung cancer ... nanotech ,nose, and a method to examine the cells ... presentations at the 3rd European Lung Cancer Conference (ELCC) ... is vital to improve lung cancer survival rates," commented ...
    ... new studies that may help doctors tailor lung cancer ... their tumors are being presented at the 3rd European ... of lung cancer treatment is to tailor the treatment ... Christie NHS Foundation Trust in Manchester, UK. "The studies ...
    ... Patients with advanced non-small cell lung cancer should only ... chemotherapy if their tumor is known to harbor EGFR ... Conference in Geneva, Switzerland. The results of ... that patients with unknown or negative mutation status should ...
    Cached Biology News:Early detection techniques offer hope for improved outcomes in lung cancer patients 2Early detection techniques offer hope for improved outcomes in lung cancer patients 3Early detection techniques offer hope for improved outcomes in lung cancer patients 4Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 2New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 3
    ...
    ... Edited by R. Edwards ... on all types of immunoassays, ... surface immunoassays and on the ... immunoassays. Essential information is also ...
    ANTI S. ENTERID LPS...
    B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
    Biology Products: